Drug Trial Radar · NCT02674854
Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
Last checked: Nov 19, 2026Latest source record: May 21, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
750
Actual
Start
Feb 2016
Primary completion
Mar 2017
Study completion Mar 2017
Sponsor
- Lead sponsor
- Aerie PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Feb 5, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to netarsudil (AR-13324) ophthalmic solution 0.02% and latanoprost ophthalmic solution 0.005%
Conditions
- Open-angle Glaucoma
- Ocular Hypertension
Interventions
PG324 Ophthalmic Solution 0.02%/0.005%Drug
1 drop daily in the evening (PM) in both eyes (OU)
Netarsudil (AR-13324) ophthalmic solution 0.02%Drug
1 drop daily in the evening (PM) in both eyes (OU)
Latanoprost ophthalmic solution 0.005%Drug
1 drop daily in the evening (PM) in both eyes (OU)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intraocular Pressure (IOP)Time frame: 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Aerie Pharmaceuticals
Bedminster, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.